ReNeuron Group Plc Product Insights, Trends & Market Analysis 2015

1
ReNeuron Group Plc Product Pipeline Review - 2015
Published on October - 2015
2
.
Report Overview
About ReNeuron Group Plc Product Pipeline Review
2015 Global Markets Directs, ReNeuron Group Plc
Product Pipeline Review - 2015, provides an
overview of the ReNeuron Group Plc s
pharmaceutical research and development focus.
This report provides comprehensive information on
the current therapeutic developmental pipeline of
ReNeuron Group Plcs, complete with comparative
analysis at various stages, therapeutics
assessment by drug target, mechanism of action
(MoA), route of administration (RoA) and molecule
type. It also reviews latest updates, and
featured news and press releases, along with
special features on late-stage and discontinued
projects. Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary data bases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team. Get
Full Details On http//www.researchbeam.com/rene
uron-group-plc-product-pipeline-review-2015-market

3
.
Report Overview
Drug profiles/records featured in the report
undergoes periodic updation following a stringent
set of processes that ensures that all the
profiles are updated with the latest set of
information. Additionally, processes including
live news deals tracking, browser based
alert-box and clinical trials registries tracking
ensure that the most recent developments are
captured on a real time basis. The report
enhances decision making capabilities and help to
create effective counter strategies to gain
competitive advantage. It strengthens RD
pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class
products. Note Certain sections in the report
may be removed or altered based on the
availability and relevance of data for the
indicated disease. Scope The report provides
brief overview of ReNeuron Group Plc including
business description, key information and facts,
and its locations and subsidiaries The report
reviews current pipeline of ReNeuron Group Plc s
human therapeutic division and enlists all their
major and minor projects
4
.
Report Overview
The report features product description and
descriptive mechanism of action for key pipeline
products along with the products developmental
history and major milestones Special feature on
out-licensed and partnered product portfolio The
report summarizes all the dormant and
discontinued pipeline projects Latest company
statement Latest news and deals relating to the
ReNeuron Group Plc s pipeline products   Reasons
to buy Evaluate ReNeuron Group Plc s strategic
position with total access to detailed
information on its product pipeline Assess the
growth potential of ReNeuron Group Plc in its
therapy areas of focus Identify new drug targets
and therapeutic classes in the ReNeuron Group Plc
s RD portfolio and develop key strategic
initiatives to reinforce pipeline in those
areas Exploit in-licensing opportunities by
identifying windows of opportunity to fill
portfolio gaps
5
Report Overview

• Develop strategic initiatives by understanding
  the focus areas of ReNeuron Group Plc and exploit
  collaboration and partnership opportunities
• Identify emerging players with potentially strong
  product portfolio and create effective
  counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by
  identifying the most promising pipeline of
  ReNeuron Group Plc
• Develop and design in-licensing and out-licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and Scope
• Explore the dormant and discontinued projects of
  ReNeuron Group Plc and identify potential
  opportunities in those areas
• Avoid Intellectual Property Rights related issues

6
Table Of Contents
List of Tables 4List of Figures 4ReNeuron Group
Plc Snapshot 5ReNeuron Group Plc Overview 5Key
Information 5Key Facts 5ReNeuron Group Plc -
Research and Development Overview 6Key
Therapeutic Areas 6ReNeuron Group Plc - Pipeline
Review 8Pipeline Products by Stage of
Development 8Pipeline Products - Monotherapy
9Pipeline Products - Partnered Products
10Partnered Products/Combination Treatment
Modalities 11ReNeuron Group Plc - Pipeline
Products Glance 12
7
Table Of Contents
ReNeuron Group Plc - Clinical Stage Pipeline
Products 12Phase II Products/Combination
Treatment Modalities 12Phase I
Products/Combination Treatment Modalities
13 ReNeuron Group Plc - Early Stage Pipeline
Products 14IND/CTA Filed Products/Combination
Treatment Modalities 14ReNeuron Group Plc - Drug
Profiles 15ReN-001 15Product Description
15Mechanism of Action 15RD Progress 15ReN-009
17Product Description 17 Mechanism of Action
17RD Progress 17
8
Table Of Contents
ReN-003 18 Product Description 18Mechanism of
Action 18RD Progress 18ReNeuron Group Plc -
Pipeline Analysis 20ReNeuron Group Plc -
Pipeline Products by Route of Administration
20ReNeuron Group Plc - Pipeline Products by
Molecule Type 21 ReNeuron Group Plc - Recent
Pipeline Updates 22ReNeuron Group Plc - Dormant
Projects 29ReNeuron Group Plc - Company
Statement 30ReNeuron Group Plc - Locations And
Subsidiaries 31 Enquiry about this report _at_
http//www.researchbeam.com/reneuron-group-plc-pro
duct-pipeline-review-2015-market/enquire-about-rep
ort
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/reneuron-group-plc-pro
duct-pipeline-review-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com